Cargando…

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody

Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is failure to activate complement dependent cytotoxicity (CDC) due to protective complement regulatory proteins, including the soluble regulator c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winkler, Mark T., Bushey, Ryan T., Gottlin, Elizabeth B., Campa, Michael J., Guadalupe, Eross S., Volkheimer, Alicia D., Weinberg, J. Brice, Patz, Edward F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489178/ https://www.ncbi.nlm.nih.gov/pubmed/28658265 http://dx.doi.org/10.1371/journal.pone.0179841

Ejemplares similares

Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis
por: Bushey, Ryan T., et al.
Publicado: (2021)

Upregulation of complement proteins in lung cancer cells mediates tumor progression
por: Kleczko, Emily K., et al.
Publicado: (2023)

Genetic Variants of CLPP and M1AP Are Associated With Risk of Non-Small Cell Lung Cancer
por: Li, Xianghan, et al.
Publicado: (2021)

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy
por: Bordron, Anne, et al.
Publicado: (2018)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Rituximab for the treatment of patients with chronic lymphocytic leukemia
por: Gentile, M, et al.
Publicado: (2010)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018)

Role of rituximab in first-line treatment of chronic lymphocytic leukemia
por: Bryan, Jeffrey, et al.
Publicado: (2011)

Large Granular Lymphocytic Leukemia: A Report of Response to Rituximab
por: Ibrahim, Uroosa, et al.
Publicado: (2017)

Clinical and Biological Relevance of Genomic Heterogeneity in Chronic Lymphocytic Leukemia
por: Friedman, Daphne R., et al.
Publicado: (2013)

RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
por: Castro, Januario E., et al.
Publicado: (2009)

Automated microarray platform for single‐cell sorting and collection of lymphocytes following HIV reactivation
por: Cortés‐Llanos, Belén, et al.
Publicado: (2023)

Single cell analysis reveals oligoclonality among “low count” monoclonal B cell lymphocytosis
por: Lanasa, Mark C., et al.
Publicado: (2009)

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
por: Avsec, Damjan, et al.
Publicado: (2021)

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2019)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer
por: Ashton, Jeffrey R., et al.
Publicado: (2018)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
por: Hörl, S, et al.
Publicado: (2013)

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
por: Hörl, S, et al.
Publicado: (2013)

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
por: Felberg, Anna, et al.
Publicado: (2020)

Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients
por: Darcy, Christabelle J, et al.
Publicado: (2014)

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Woyach, Jennifer A, et al.
Publicado: (2009)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
por: Sriwijitalai, Won, et al.
Publicado: (2019)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Improvement of Paraneoplastic Limbic Encephalitis after Systemic Treatment with Rituximab in a Patient with B-Cell Chronic Lymphocytic Leukemia
por: Nogai, Hendrik, et al.
Publicado: (2013)

Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab
por: Chakraborty, Subhankar, et al.
Publicado: (2011)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report
por: Sturm, Isrid, et al.
Publicado: (2008)

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Fraser, G., et al.
Publicado: (2018)

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
por: Pescovitz, Mark D., et al.
Publicado: (2014)

High-Intensity Interval Training in Older Adults With Treatment Naive Chronic Lymphocytic Leukemia
por: Bartlett, David, et al.
Publicado: (2021)

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
por: Robak, Tadeusz, et al.
Publicado: (2021)

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)
por: Sitlinger, Andrea, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pjobn2j052vnsm473oc38rjfe7